APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Peripheral Neuropathy Treatment

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Selected research

Market Analysis & Forecast

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Peripheral Neuropathy Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

Read the full market overview

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

This report presents an overview of global market for Chemotherapy Induced Peripheral Neuropathy Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chemotherapy Induced Peripheral Neuropathy Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Chemotherapy Induced Peripheral Neuropathy Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Chemotherapy Induced Peripheral Neuropathy Treatment sales, projected growth trends, production technology, application and end-user industry.

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Company

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application

Platinum Agents

Taxanes

Vinca Alkaloids

Others

Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Peripheral Neuropathy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Peripheral Neuropathy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Calcium Channel α2-delta Ligands Major Manufacturers Table 3. Antidepressants Major Manufacturers Table 4. Opioids Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Platinum Agents Major Manufacturers Table 8. Taxanes Major Manufacturers Table 9. Vinca Alkaloids Major Manufacturers Table 10. Others Major Manufacturers Table 11. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends Table 12. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers Table 13. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges Table 14. Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2026) Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2027-2032) Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026) & (K Units) Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032) & (K Units) Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021-2026) Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2027-2032) Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2021-2026) Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Product Type & Application Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2026) Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2027-2032) Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2026) Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2027-2032) Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2026) & (US$/Unit) Table 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2027-2032) & (US$/Unit) Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2026) Table 52. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2027-2032) Table 53. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 55. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 56. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2026) Table 57. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2027-2032) Table 58. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2026) & (US$/Unit) Table 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2027-2032) & (US$/Unit) Table 60. Aptinyx Inc Company Information Table 61. Aptinyx Inc Business Overview Table 62. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 64. Aptinyx Inc Recent Development Table 65. Asahi Kasei Pharma Corp Company Information Table 66. Asahi Kasei Pharma Corp Business Overview Table 67. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 69. Asahi Kasei Pharma Corp Recent Development Table 70. Regenacy Pharmaceuticals Company Information Table 71. Regenacy Pharmaceuticals Business Overview Table 72. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 74. Regenacy Pharmaceuticals Recent Development Table 75. MAKScientific LLC Company Information Table 76. MAKScientific LLC Business Overview Table 77. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 79. MAKScientific LLC Recent Development Table 80. Metys Pharmaceuticals AG Company Information Table 81. Metys Pharmaceuticals AG Business Overview Table 82. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 84. Metys Pharmaceuticals AG Recent Development Table 85. Nemus Bioscience Inc Company Information Table 86. Nemus Bioscience Inc Business Overview Table 87. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 89. Nemus Bioscience Inc Recent Development Table 90. PledPharma Company Information Table 91. PledPharma Business Overview Table 92. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 94. PledPharma Recent Development Table 95. Sova Pharmaceuticals Inc Company Information Table 96. Sova Pharmaceuticals Inc Business Overview Table 97. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 99. Sova Pharmaceuticals Inc Recent Development Table 100. DermaXon LLC Company Information Table 101. DermaXon LLC Business Overview Table 102. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 104. DermaXon LLC Recent Development Table 105. Kineta Inc Company Information Table 106. Kineta Inc Business Overview Table 107. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 109. Kineta Inc Recent Development Table 110. Krenitsky Pharmaceuticals Inc Company Information Table 111. Krenitsky Pharmaceuticals Inc Business Overview Table 112. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 114. Krenitsky Pharmaceuticals Inc Recent Development Table 115. PeriphaGen Company Information Table 116. PeriphaGen Business Overview Table 117. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 119. PeriphaGen Recent Development Table 120. Apexian Pharma Company Information Table 121. Apexian Pharma Business Overview Table 122. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 124. Apexian Pharma Recent Development Table 125. WinSanTor Company Information Table 126. WinSanTor Business Overview Table 127. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio Table 129. WinSanTor Recent Development Table 130. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 131. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 132. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 133. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 134. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2021-2026) & (US$/Unit) Table 135. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2027-2032) & (US$/Unit) Table 136. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 137. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 138. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 139. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 140. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2021-2026) & (US$/Unit) Table 141. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2027-2032) & (US$/Unit) Table 142. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 146. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 147. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 148. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2021-2026) & (US$/Unit) Table 149. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2027-2032) & (US$/Unit) Table 150. United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 151. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 152. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 153. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 154. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 155. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 156. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 157. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2021-2026) & (US$/Unit) Table 158. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2027-2032) & (US$/Unit) Table 159. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 160. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 161. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 162. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 163. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2021-2026) & (US$/Unit) Table 164. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 169. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 170. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 171. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2021-2026) & (US$/Unit) Table 172. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2027-2032) & (US$/Unit) Table 173. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 174. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 175. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 176. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 177. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 178. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 179. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 180. Switzerland Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 181. Sweden Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 182. Poland Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 183. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 184. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 185. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 186. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 187. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2021-2026) & (US$/Unit) Table 188. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2027-2032) & (US$/Unit) Table 189. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 190. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 191. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 192. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 193. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2021-2026) & (US$/Unit) Table 194. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2027-2032) & (US$/Unit) Table 195. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 196. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 197. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 198. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 199. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2021-2026) & (US$/Unit) Table 200. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2027-2032) & (US$/Unit) Table 201. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 202. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 203. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 204. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 205. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2021-2026) & (US$/Unit) Table 206. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2027-2032) & (US$/Unit) Table 207. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 208. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 209. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 210. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 211. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 212. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 213. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2021-2026) & (US$/Unit) Table 214. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2027-2032) & (US$/Unit) Table 215. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 216. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 217. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 218. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 219. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 220. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 221. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 222. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 223. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2026) & (K Units) Table 224. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2027-2032) & (K Units) Table 225. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2021-2026) & (US$/Unit) Table 226. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Type (2027-2032) & (US$/Unit) Table 227. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 228. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 229. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2026) & (K Units) Table 230. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2027-2032) & (K Units) Table 231. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2021-2026) & (US$/Unit) Table 232. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Application (2027-2032) & (US$/Unit) Table 233. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 234. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 235. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 236. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 237. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021-2026) & (K Units) Table 238. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2027-2032) & (K Units) Table 239. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2021-2026) & (US$/Unit) Table 240. SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Country (2027-2032) & (US$/Unit) Table 241. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 242. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 243. Chile Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 244. Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 245. Peru Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 246. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 247. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 248. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 249. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 250. Iran Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 251. Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Table 252. Key Raw Materials Table 253. Raw Materials Key Suppliers Table 254. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List Table 255. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List Table 256. Research Programs/Design for This Report Table 257. Authors List of This Report Table 258. Secondary Sources Table 259. Primary Sources List of Figures Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Image Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Calcium Channel α2-delta Ligands Image Figure 5. Antidepressants Image Figure 6. Opioids Image Figure 7. Others Image Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Platinum Agents Image Figure 11. Taxanes Image Figure 12. Vinca Alkaloids Image Figure 13. Others Image Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2021-2032) & (US$ Million) Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2032) Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2021-2032) & (K Units) Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2021-2032) & (K Units) Figure 23. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2021-2032) & (K Units) Figure 24. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2021-2032) & (K Units) Figure 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2032) Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2032) Figure 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2032) Figure 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2032) Figure 42. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2021-2032) Figure 43. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2021-2032) Figure 44. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2021-2032) Figure 45. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2021-2032) Figure 46. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country (2021-2032) F

Scope & coverage.

Types
  • Calcium Channel α2-delta Ligands
  • Antidepressants
  • Opioids
  • Others
Applications
  • Platinum Agents
  • Taxanes
  • Vinca Alkaloids
  • Others
Companies covered
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Regenacy Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Kineta Inc
  • Krenitsky Pharmaceuticals Inc
  • PeriphaGen
  • Apexian Pharma
  • WinSanTor

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Type
  3. 1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Calcium Channel α2-delta Ligands
  5. 1.2.3 Antidepressants
  6. 1.2.4 Opioids
  7. 1.2.5 Others
  8. 1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application
  9. 1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Platinum Agents
  11. 1.3.3 Taxanes
  12. 1.3.4 Vinca Alkaloids
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
  1. 2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
  2. 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Drivers
  3. 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region
  3. 3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2021-2026)
  5. 3.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2027-2032)
  6. 3.2.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
  9. 3.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2021-2026)
  11. 3.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2027-2032)
  12. 3.4.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers
  2. 4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers
  6. 4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers, Product Type & Application
  13. 4.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market CR5 and HHI
  16. 4.8.2 2025 Chemotherapy Induced Peripheral Neuropathy Treatment Tier 1, Tier 2, and Tier 3
5 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Type
  1. 5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type
  2. 5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type
  6. 5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021-2032)
  9. 5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type
6 Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application
  1. 6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application
  2. 6.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application
  6. 6.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021-2032)
  9. 6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application
7 Company Profiles
  1. 7.1 Aptinyx Inc
  2. 7.1.1 Aptinyx Inc Company Information
  3. 7.1.2 Aptinyx Inc Business Overview
  4. 7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  6. 7.1.5 Aptinyx Inc Recent Developments
  7. 7.2 Asahi Kasei Pharma Corp
  8. 7.2.1 Asahi Kasei Pharma Corp Company Information
  9. 7.2.2 Asahi Kasei Pharma Corp Business Overview
  10. 7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  12. 7.2.5 Asahi Kasei Pharma Corp Recent Developments
  13. 7.3 Regenacy Pharmaceuticals
  14. 7.3.1 Regenacy Pharmaceuticals Company Information
  15. 7.3.2 Regenacy Pharmaceuticals Business Overview
  16. 7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  18. 7.3.5 Regenacy Pharmaceuticals Recent Developments
  19. 7.4 MAKScientific LLC
  20. 7.4.1 MAKScientific LLC Company Information
  21. 7.4.2 MAKScientific LLC Business Overview
  22. 7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  24. 7.4.5 MAKScientific LLC Recent Developments
  25. 7.5 Metys Pharmaceuticals AG
  26. 7.5.1 Metys Pharmaceuticals AG Company Information
  27. 7.5.2 Metys Pharmaceuticals AG Business Overview
  28. 7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  30. 7.5.5 Metys Pharmaceuticals AG Recent Developments
  31. 7.6 Nemus Bioscience Inc
  32. 7.6.1 Nemus Bioscience Inc Company Information
  33. 7.6.2 Nemus Bioscience Inc Business Overview
  34. 7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  36. 7.6.5 Nemus Bioscience Inc Recent Developments
  37. 7.7 PledPharma
  38. 7.7.1 PledPharma Company Information
  39. 7.7.2 PledPharma Business Overview
  40. 7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  42. 7.7.5 PledPharma Recent Developments
  43. 7.8 Sova Pharmaceuticals Inc
  44. 7.8.1 Sova Pharmaceuticals Inc Company Information
  45. 7.8.2 Sova Pharmaceuticals Inc Business Overview
  46. 7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  48. 7.8.5 Sova Pharmaceuticals Inc Recent Developments
  49. 7.9 DermaXon LLC
  50. 7.9.1 DermaXon LLC Company Information
  51. 7.9.2 DermaXon LLC Business Overview
  52. 7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  54. 7.9.5 DermaXon LLC Recent Developments
  55. 7.10 Kineta Inc
  56. 7.10.1 Kineta Inc Company Information
  57. 7.10.2 Kineta Inc Business Overview
  58. 7.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  60. 7.10.5 Kineta Inc Recent Developments
  61. 7.11 Krenitsky Pharmaceuticals Inc
  62. 7.11.1 Krenitsky Pharmaceuticals Inc Company Information
  63. 7.11.2 Krenitsky Pharmaceuticals Inc Business Overview
  64. 7.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  66. 7.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
  67. 7.12 PeriphaGen
  68. 7.12.1 PeriphaGen Company Information
  69. 7.12.2 PeriphaGen Business Overview
  70. 7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  72. 7.12.5 PeriphaGen Recent Developments
  73. 7.13 Apexian Pharma
  74. 7.13.1 Apexian Pharma Company Information
  75. 7.13.2 Apexian Pharma Business Overview
  76. 7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  78. 7.13.5 Apexian Pharma Recent Developments
  79. 7.14 WinSanTor
  80. 7.14.1 WinSanTor Company Information
  81. 7.14.2 WinSanTor Business Overview
  82. 7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
  84. 7.14.5 WinSanTor Recent Developments
8 North America
  1. 8.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  2. 8.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  3. 8.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  4. 8.1.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2032)
  5. 8.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  6. 8.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  7. 8.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  8. 8.2.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2032)
  9. 8.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  10. 8.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  2. 9.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  3. 9.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  4. 9.1.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2032)
  5. 9.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  6. 9.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  7. 9.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  8. 9.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2032)
  9. 9.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  10. 9.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  2. 10.1.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  3. 10.1.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  4. 10.1.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2032)
  5. 10.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  6. 10.2.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  7. 10.2.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  8. 10.2.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  2. 11.1.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  3. 11.1.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  4. 11.1.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2032)
  5. 11.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  6. 11.2.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  7. 11.2.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  8. 11.2.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2032)
  9. 11.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  10. 11.3.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
  2. 12.1.1 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2021-2032)
  5. 12.2 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
  6. 12.2.1 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2021-2032)
  9. 12.3 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
  10. 12.3.1 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Chemotherapy Induced Peripheral Neuropathy Treatment Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain Analysis
  2. 13.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process
  6. 13.2 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
  9. 13.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst